Stopping clinical trials by design

  title={Stopping clinical trials by design},
  author={John Whitehead},
  journal={Nature Reviews Drug Discovery},
Before any clinical trial begins, a detailed trial protocol must be prepared. The authority of the trial results will depend on the quality of this document. In many protocols, a key component is a plan for a series of interim analyses of the accumulating trial data, and a 'stopping rule' based on them. Such a rule might be intended to prevent participants from continuing to receive a drug that already seems to be unsafe, or to allow a successful drug to become generally available as soon as… CONTINUE READING

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 12 extracted citations

Portfolio Decisions in Early Development

Pharmaceutical Medicine • 2012
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 25 references

Design and analysis of group sequential clinical trials with multiple primary endpoints

M. M. Kosorok, Y. Shi, D. L. DeMets
Biometrics • 2004

The double triangular test in practice

J. Whitehead, S. Todd
Pharm . Statist . • 2004

A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early - stage breast cancer

P. E. Goss
N . Engl . J . Med . • 2003

On the inefficiency of the adaptive design for monitoring clinical trials

A. A. Tsiatis, C. R. Mehta
Biometrika • 2003

Similar Papers

Loading similar papers…